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Background: Population-based data on the burden of chronic kidney disease (CKD) in sub-Saharan Africa is still
very limited. We assessed the prevalence and determinants of CKD, and evaluated the concordance of commonly
advocated estimators of glomerular filtration rate (eGFR) in a mixed ancestry population from South Africa.
Methods: Participants were a population-based sample of adults selected from the Bellville-South community in
the metropolitan city of Cape Town. eGFR was based on the Cockroft-Gault (CG), Modification of Diet in Kidney
Disease (MDRD) and CKD Epidemiology Collaboration (CKD-EPI) equations (with and without adjustment for
ethnicity). Kidney function staging used the Kidney Disease Outcome Quality Initiative (KDOQI) classification.
Logistic regressions and kappa statistic were used to investigate determinants of CKD and assess the agreement
between different estimators.
Results: The crude prevalence of CKD stage 3–5 was 14.8% for Cockcroft-Gault, 7.6% and 23.9% respectively for the
MDRD with and without ethnicity correction, and 7.4% and 17.3% for the CKD-EPI equations with and without
ethnicity correction. The highest agreement between GFR estimators was between MDRD and CKD-EPI equations,
both with ethnicity correction, Kappa 0.91 (95% CI: 0.86-0.95), correlation coefficient 0.95 (95% CI: 0.94-0.96). In
multivariable logistic regression models, sex, age and known hypertension were consistently associated with CKD
stage 3–5 across the 5 estimators.
Conclusions: The prevalence of CKD stages greater than 3 is the highest reported in Africa. This study provides
evidence for support of the CKD-EPI equation for eGFR reporting and CKD classification.
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Chronic kidney disease (CKD) has become a major public
health problem worldwide, and this has necessitated the
development of guidelines for the definition and classifica-
tion of the disease by the Kidney Disease Outcomes Qual-
ity Initiative (KDOQI) [1,2]. It has been estimated that
approximately 500 million individuals globally have CKD,* Correspondence: rte@sun.ac.za
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reproduction in any medium, provided the ora number that translates to about 1 in 10 affected adults
[3]. The terminal stage of CKD, end stage renal disease
(ESRD), requires renal replacement therapy or kidney trans-
plant at enormous cost to individuals and national health
budgets. It is estimated that over 1.4 million people world-
wide receive renal replacement therapy to prolong life, with
the incidence increasing by 8% annually [4,5]. Furthermore,
the presence of CKD is associated with premature mor-
tality from cardiovascular diseases (CVD). The risk of
cardiac death is increased by 46% in people with a glom-
erular filtration rate (GFR) between 30 and 60 ml/min
per 1.73 m2 independent of traditional cardiovascularLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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The magnitude of CKD in Sub-Saharan Africa (SSA)
countries is still poorly characterized, although there
are speculations that the incidence rates are 3–4 times
higher than those in developed countries [7]. In general,
available data on CKD in Africa have been largely derived
from hospital-based studies conducted in tertiary health
care facilities and very few from community-based studies
[8,9]. Some of the studies reported on the performance
of the GFR estimating equations rather than the preva-
lence of CKD [10-12].
The reported high fatality rate associated with CKD in
Africa has been attributed to a number of factors in-
cluding the increasing prevalence of infectious diseases,
late referrals of individuals with CKD to specialists, poor
prognosis, limited renal replacement therapy, and the lack
of agreement on the definition of CKD and standardisa-
tion of tests that are currently used for diagnosing the
disease [10-13]. With specific reference to CKD diagno-
sis, the three commonly used estimators of GFR include
the Cockcroft-Gault, the Modification of Diet in Renal
Disease (MDRD) and the CKD Epidemiology Collabor-
ation (CKD-EPI) equations, and each diagnoses a differ-
ent subgroup of patients with CKD [11,12,14,15]. The
more acclaimed MRDR and CKD-EPI equations apply a
correction factor for ethnicity, which may substantially
affect the diagnosis of CKD without being necessarily
valid in all settings [11,12]. Therefore, in addition to
improving the knowledge base on the magnitude of CKD
at the population level in Africa, efforts are needed to
improve the accuracy of the diagnosis of the disease.
The aim of the present study was to assess the magni-
tude and determinants of CKD in a community based
cohort, and evaluate the agreement between commonly
advocated kidney function estimators in a mixed ances-
try African population.
Methods
Study setting and population
Study participants were members of a cohort study con-
ducted in Bellville South, a mixed ancestry township
formed in the late 1950s, and which is located in the
metropolitan city of Cape Town, South Africa. The mixed
ancestry is a South African population group comprising
32-43% Khoisan, 20–36% Bantu-speaking African, 21 – 28%
European and 9 – 11% Asian ancestry [16]. The study
setting, survey design and procedures have been de-
scribed in details elsewhere [17,18]. Briefly, eligible par-
ticipants were invited to take part in a community based
survey from January 2008 to March 2009 (Cohort 1),
and January 2011 to November 2011 (Cohort 2). The
study was approved by the Cape Peninsula University of
Technology, Faculty of Health and Wellness Sciences
ethics committee (Reference Number: CPUT/HW-REC2008/002 and CPUT/HW-REC 2010). The study was
conducted according to the Code of Ethics of the World
Medical Association (Declaration of Helsinki). All par-
ticipants signed written informed consent after all the
procedures were fully explained in the language of
their choice.
Clinical data
All consenting participants received a standardized inter-
view and physical examination during which blood pressure
was measured according to the World Health Organisation
(WHO) guidelines [19] using a semi-automatic digital
blood pressure monitor (Rossmax PA, USA) on the right
arm in a sitting position. Other clinical measurements
included the body weight, height, waist and hip circum-
ferences. Weight (to the nearest 0.1 kg) was determined
in a subject wearing light clothing and without shoes
and socks, using a Sunbeam EB710 digital bathroom scale,
which was calibrated and standardized using a weight of
known mass. Waist circumference was measured using a
non-elastic tape at the level of the narrowest part of the
torso, as seen from the anterior view. All anthropometric
measurements were performed three times and their
average used for analysis. Participants with no history of
doctor diagnosed diabetes mellitus underwent a 75 g
oral glucose tolerance test (OGTT) as recommended by
the WHO [20].
Laboratory measurements
Blood samples were collected after an overnight fast and
processed for further biochemical analysis. Plasma glu-
cose was measured by enzymatic hexokinase method
(Cobas 6000, Roche Diagnostics, Germany) and glycated
haemoglobin (HbA1c) by turbidimetric inhibition im-
munoassay (Cobas 6000, Roche Diagnostics, Germany)
this being a National Glycohaemoglobin Standardisation
Programme (NGSP) certified method. Creatinine levels
were measured using the standardized creatinine assay
(Cobas 6000, Roche Diagnostics, Germany).
Definitions and calculations
Diabetes status was based on a history of doctor-diagnosis,
a fasting plasma glucose >=7.0 mmol/l and/or a 2-hour
post-OGTT plasma glucose >11.1 mmol/l. Hypertension
was based on a history of doctor diagnosed hypertension
and/or receiving medications for hypertension or average
systolic blood pressure ≥140 mmHg and/or average dia-
stolic blood pressure ≥90 mmHg. Kidney function was
assessed through estimated glomerular filtration rate
(eGFR) for which both the Cockcroft-Gault equation [21]
(with correction for the body surface area using the for-
mula by Du Bois) [22], 4-variable Modification of Diet
in Renal Disease (MDRD) equation [23,24] applicable to
standardised serum creatinine values, and the Chronic
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equation [25] were used, with and without ethnicity
adjustment for all participants. Staging of kidney function
was based on the National Kidney Foundation Disease
Outcomes Quality Initiative (NKF-KDOQI) classification
[26]. An eGFR<60 ml/min was used to define chronic
kidney disease (or CKD stage 3–5).
Statistical analysis
The R statistical software version 2.13.0 (13-04-2011),
(The R Foundation for Statistical Computing, Vienna,
Austria) was used for data analysis. General characteris-
tics of the study groups are summarized as count and
percentage for qualitative variable, mean and standard
deviation (SD) or median and 25th-75th percentiles for
quantitative variables. Group comparisons used chi square
tests and equivalents for qualitative variables, and Student’s
t-test and non-parametric equivalents for quantitative
variables. Agreement between kidney function estima-
tors was assessed on the continuous scale with the use
of the Spearman’s correlation, and across categories of
estimated kidney function with the use of the kappa
statistic. The age standardized prevalence of CKD was
calculated in ten-year-intervals using the standard world
population distribution as projected by the WHO for
2000–2025 [27]. The direct standardization was applied.
Predictors of CKD were investigated with the use of lo-
gistic regression models. A p-value <0.05 was used to
characterise statistically significant results.
Results
Baseline characteristic of the study population
The initial study sample comprised 1256 subjects, 54 of
whom had missing data on serum creatinine or any of
the variables included in the estimation of kidney func-
tion (age, sex or weight) and were therefore excluded.
The final sample included 1202 subjects of whom905
(75.3%) were females. The general characteristics of the
study population are summarised in Table 1. The mean
age was 52.9 years, with a borderline difference between
men and women (54.2 vs. 52.4 years, p=0.06). With the
exception of fasting plasma glucose (p=0.55), HbA1c
(p=0.75), triglycerides (p=0.17), serum cotinine (p=0.05)
and prevalent diabetes (p=0.80), significant differences
were observed between men and women with regard to
several baseline characteristics.
Correlation between eGFR as calculated by cockcroft-
gault, MDRD, and CKD-EPI equations
The mean estimated glomerular filtration rate (eGFR)
was 91.7 ml/min (Cockcrof-Gault), 97.3 ml/min (MDRD
with ethnicity correction), 75.6 ml/min (MDRD without
ethnicity correction), 94.3 ml/min (CKD-EPI with ethnicity
correction) and 81.4 ml/min (CKD-EPI without ethnicitycorrection) (Table 1). Compared with men, eGFR in
women was higher based on Cockcroft-Gault estimator,
and lower based on all other estimators (all p≤0.02).
There was a positive and significant correlation between
different estimates of GFR. The Spearson’s correlation
coefficient (95% confidence interval) was 0.84 (0.82-
0.85) for Cockcroft-Gault vs. MDRD (with or without
ethnicity correction), 0.86 (0.85-0.87) for Cockcroft-
Gault vs. CKD-EPI (with or without ethnicity correction)
and 0.95 (0.94-0.96) MDRD vs. CKD-EPI (Figure 1).
Equivalent results were 0.86 (0.82-0.88), 0.70 (0.63-0.75)
and 0.94 (0.92-0.95) in men and, 0.88 (0.87-0.90), 0.76
(0.73-0.79) and 0.96 (0.95-0.96) in women.
Staging of kidney function by different estimators
None of the participants had an eGFR value <15 ml/min
based on any of the estimators. Therefore, kidney func-
tion staging was based on 4 categories: ≥90 ml/min,
60–90 ml/min, 30–60 ml/min, and <30 ml/min. There
was a substantial variation in the number of participants
ranked within kidney function strata by different estima-
tors (Figure 2). The highest agreement was observed when
comparing the ranking based on the MDRD with that
based on CKD-EPI equations (both with ethnicity cor-
rection) with a kappa statistic (95% confidence interval)
of 0.82 (0.79-0.85). Among participants ranked according
to the MDRD formula without ethnicity correction, the
CKD-EPI equation with ethnicity correction always re-
classified more participants within more favourable than
within less strata of kidney function (Figure 2). For in-
stance, among those with an eGFR of 30–60 ml/min
based on MDRD with correction (n=88) the CKD-EPI
with correction reclassified 9 (10%) in the stratum 60–
90 ml/min and only 3 (3%) in the stratum <30 ml/min.
Equivalent results for those within the MDRD stratum
60–90 ml/min (n=531) were 98 (18.4%) and 6 (1.1%).
Similar patterns were observed when comparing MDRD
and CKD-EPI equivalents without correction for ethni-
city, with however a much higher proportions of par-
ticipants being reclassified, resulting in only average
agreement [kappa 0.63 (0.59-0.67)]. The agreement was
always lower than average when comparing the Cockcroft-
Gault equation with any of the other estimators, with
kappa statistic ranging from 0.35 (Cockcroft-Gault vs.
MDRD without correction) to 0.56 (Cockcroft-Gault vs.
CKD-EPI with correction); Figure 2.
Crude and age-adjusted prevalence of CKD stage 3–5 and
agreement between estimators
The crude prevalence of CKD stages 3–5 is shown in
Table 1 for the total population and by sex. The highest
overall prevalence of 26.7%) was observed in women
with the MDRD equation without ethnicity correction,
and with the Cockcoft-Gault equation in men (19.2%).
Table 1 Clinical characteristics of the study population overall and by sex
Variables Male Female p-value overall
N 297 905 1202
Mean age, year (SD) 54.2 (15.4) 52.4 (14.6) 0.06 52.9 (14.8)
Mean body mass index, kg/m2 (SD) 26.6 (6.4) 31.0 (7.1) <0.0001 29.9 (7.2)
Mean waist circumference, cm (SD) 94 (15) 97 (15) 0.002 96 (15)
Mean hip circumference, cm (SD) 101 (11) 112 (14) <0.0001 109 (14)
Mean waist-to-hip ratio, (SD) 0.93 (0.08) 0.87 (0.09) <0.0001 0.88 (0.09)
Mean systolic blood pressure, mmHg (SD) 128 (19) 124 (20) 0.0006 125 (20)
Mean diastolic blood pressure, mmHg (SD) 78 (14) 75 (12) 0.001 76 (13)
Mean fasting blood glucose, mmol/l (SD) 6.4 (3.4) 6.3 (2.6) 0.55 6.3 (3.0)
Mean 2-hour blood glucose, mmol/l (SD) 6.8 (3.0) 7.5 (3.6) 0.001 7.4 (3.5)
Mean HbA1c,% (SD) 6.3 (1.6) 6.3 (1.4) 0.75 6.3 (1.4)
Mean total cholesterol, mmol/l (SD) 5.3 (1.1) 5.6 (1.2) 0.0001 5.6 (1.2)
Mean triglycerides, mmol/l (SD) 1.5 (0.9) 1.5 (0.9) 0.17 1.5 (0.9)
Mean HDL cholesterol, mmol/l (SD) 1.2 (0.4) 1.3 (0.3) 0.0001 1.3 (0.4)
Mean LDL cholesterol, mmol/l (SD) 3.4 (1.0) 3.7 (1.0) 0.0006 3.6 (1.0)
Median serum cotinine, (25th-75th percentiles) 10 (10–311) 10 (9–378) 0.05 10 (9–284)
Median GGT, (25th-75th percentiles) 32 (23–49) 25 (18–39) <0.0001 27 (19–42)
Any diabetes, n (%) 80 (26.9) 237 (26.2) 0.80 317 (26.4%)
Current smoking, n (%) 146 (49.2) 341 (37.7) 0.0005 487 (40.5)
Estimated glomerular filtration rate (eGFR), ml/min
Cockcroft-Gault, mean (SD) 84.1 (27.0) 94.2 (33.7) <0.0001 91.7 (32.5)
Cockcroft-Gault <60, n (%) 57 (19.2) 121 (13.4) 0.014 178 (14.8)
4-v-MDRD, mean (SD) 102.8 (26.5) 95.4 (28.0) <0.0001 97.3 (27.8)
4-v-MDRD <60, n (%) 15 (5.0) 77 (8.5) 0.05 92 (7.6)
4-v-MDRD without ethnicity correction, mean (SD) 79.9 (20.6) 74.2 (21.8) <0.0001 75.6 (21.6)
4-v-MDRD without ethnicity correction <60, n (%) 45 (15.1) 242 (26.7) <0.0001 287 (23.9)
CKD-EPI, mean (SD) 97.2 (23.0) 93.4 (25.7) 0.02 94.3 (25.1)
CKD-EPI <60, n (%) 17 (5.7) 72 (8.0) 0.20 89 (7.4)
CKD-EPI without ethnicity correction, mean (SD) 83.9 (19.9) 80.6 (22.1) 0.02 81.4 (21.6)
CKD-EPI without ethnicity correction <60, n (%) 38 (12.8) 170 (18.8) 0.02 208 (17.3)
Abbreviations: CKD-EPI, Chronic Kidney Disease Collaboration Epidemiology; GGT, gamma glutamyltransferase; HbA1c, glycosylated haemoglobin A1c; HDL-C,
high density lipoprotein-cholesterol; LDL-C, low density lipoprotein-cholesterol; 4-v-MDRD, four variable Modification of Diet in Renal Disease; SD,
standard deviation.
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except for the the Cockcoft-Gault equation (p=0.014)
(Table 1). The age-standardised prevalence (95% confi-
dence interval) of CKD stage 3–5 was 7.2% (5.8-8.6) for
Cockcroft-Gault, 3.9% (3.1-4.7) and 13.0% (11.2-14.8)
respectively for the MDRD with and without ethnicity
correction, and 3.5% (2.7-4.3) and 8.7% (7.5-9.9) for the
CKD-EPI equations with and without ethnicity correc-
tion. Regardless of the estimator, the prevalence of CKD
increased with advancing age, with an accelerated pat-
tern after 50 years of age (Figure 3).
The highest agreement between GFR estimators to diag-
nosed CKD stage 3–5 was observed when comparing the
MDRD and CKD-EPI equations, both with ethnicity cor-
rection, kappa 0.91 (95% confidence interval: 0.86-0.95),
followed by their equivalents without correction, kappa0.79 (0.74-0.83) (Table 2). This also applied to a large
extent to men and women considered separately. The
agreement for other paired comparisons was low to aver-
age. With two exceptions, the confidence interval around
kappa estimates in men and women always overlapped,
suggesting that estimates were not appreciably different
by sex.
Determinants of chronic kidney disease, stages 3–5
Age and sex adjusted determinants of prevalent CKD stage
3–5 are shown in Table 3, separately for each of the
estimators. In multivariable logistic regression models
with mutual adjustment for significant determinants in
sex and age adjusted models, sex, age and known hyper-
tension were consistently associated with CKD stage
3–5 across the 5 estimators (Table 4) with similar range of
Figure 1 Spearman’s correlation for the three GFR estimating
equations. A) four variable Modification of Diet in Renal Disease
(4-v-MDRD) vs Cockcroft-Gault (CG), B) Chronic Kidney Disease
Collaboration Epidemiology (CKD-EPI) vs CG and C) CKD-EPI
vs 4-v-MDRD.
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based on ethnicity corrected MDRD or CKD-EPI equa-
tions, while body mass index was associated with Cockroft-
Gault formulae defined CKD stage 3–5.
Discussion
The present study investigated the prevalence of CKD
using, MDRD, CKD-EPI and the Cockcroft-Gault equa-
tions. We obtained different estimates of GFR by the
three commonly used CKD equations, resulting in vary-
ing prevalence rates of CKD in the mixed ancestry
population from South Africa. The highest agreement
was observed when comparing the MDRD and CKD-EPI
equations, both with ethnicity correction, followed by
their equivalents without correction. Based on the South
African Renal Society CKD guidelines that omit the cor-
rection factor except for black Africans, the prevalence
of CKD stages greater than 3 is the highest reported in
Africa thus far. In this first community-based study on
the prevalence of CKD in an urban population from
South Africa, regardless of the estimator, the prevalence
of CKD increased with advancing age, with an acceler-
ated pattern after 50 years of age. Risk factors for CKD
such as sex, age and hypertension were similar to those
reported in developed countries.
To our knowledge, there exist only two detailed re-
ports on the prevalence of CKD in populations from
Sub-Saharan Africa [9,11]. Both studies reported preva-
lence rates much lower than obtained in this study using
either MDRD and/or CKD-EPI equations, but higher with
Cockcroft-Gault [11]. Similar to other population studies,
majority of our participants with eGFR < 60 ml/min were
stage 3 and none were stage 5 (eGFR < 15 ml/min)
[11,28,29]. Progression of CKD to ESRD is reported to
be at a slower rate in women [30], but we found a higher
CKD prevalence in females than in males similar to other
epidemiological CKD screening studies [31-33] though
some studies have reported higher rates in men [9,28].
Gender-specific differences in glomerular structure, hemo-
dynamic condition and the effect of sex hormones on
kidney cells are some of the factors believed to con-
tribute to gender differences [34]. In our study most
women were probably postmenopausal as their mean
age was 52.4 years and might therefore explain the
divergent findings.
The Cockcroft-Gault, MDRD and CKD-EPI equations
have been adopted and used globally as cost-effective
Figure 2 Chronic kidney disease (CKD) staging and cross classification of participants into 4 eGFR categories (eGFR ≥90 ml/min,
60–90 ml/min, 30–60 ml/min and <30 ml/min) using the Cockcroft-Gault (CG), 4-variable Modification of Renal Disease (4-v-MDRD)
and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations. The three equations were compared to each other in
classifying the study population into CKD stages using Cohen’s kappa statistics, and the kappa index for each comparison is indicated.
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and these equations have been validated in a few African
studies [9-12]. Currently in South Africa, the MDRD
and Cockcroft-Gault formulae are the recommended
methods for the estimation of GFR, but we observed a
poor agreement between these two equations. Insteadthe agreements were always higher between the MDRD
and CKD-EPI equations. Whilst the South African, Renal
Society CKD guidelines recommend the MDRD with
ethnicity correction factor only in black Africans, it does
not account for the African ancestry in the mixed ances-
try population of South Africa. Nevertheless, evaluation
Figure 3 Age-standardised prevalence of CKD stage 3–5
according to GFR estimating equations Cockcroft-Gault 4-variable
Modification of Renal Disease (4-v-MDRD) and Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equations.
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individuals from Africa have shown that the MDRD and
CKD-EPI formulae performed better when the African-
American-derived ethnicity correction factor was excluded
[10-12]. Although we demonstrated the best agreement
and similar CKD rates with the MDRD and CKD-EPI
equations with the ethnicity correction factor, further
studies are required to evaluate these equations against
the gold standard in this mixed ancestry population of
South Africa.
This study also adds to already existing evidence that
hypertension is one of the major contributors to the de-
velopment and/or progression of CKD in South Africa
and worldwide [12,35,36]. In our population the pres-
ence of hypertension doubled the risk of prevalent CKD.
Hypertension affects approximately 25% of the adultTable 2 Agreement between different kidney function estima
95% confidence interval)
Estimator 1 Estimator 2 Men
Cockcroft-Gault MDRD corrected 0.27 (0
MDRD 0.57 (0
CKD-EPI corrected 0.35 (0
CKD-EPI 0.64 (0
MDRD corrected MDRD 0.46 (0
CKD-EPI corrected 0.87 (0
CKD-EPI 0.53 (0
MDRD CKD-EPI corrected 0.51 (0
CKD-EPI 0.85 (0
CKD-EPI corrected CKD-EPI 0.58 (0
CG, Cockcroft-Gault; CKD-EPI, Chronic Kidney Disease Collaboration Epidemiology; Dpopulation and is a cause of CKD in 21% of patients on
renal replacement therapy in the South African Registry
[37]. CKD is also a major contributor of secondary
dyslipidaemia and is characterized by specific abnormal-
ities involving all the lipoprotein classes, with variations
depending on the degree of renal impairment, etiology
of primary renal disease and the method of dialysis [38].
However, in this study, triglycerides were only associ-
ated with CKD based on ethnicity corrected MDRD or
CKD-EPI equation, and only in the absence of other
covariates in logistic regression models.
Our study has some limitations. This study was con-
ducted at only one geographical site, and may not ad-
equately reflect all the mixed ancestry population groups
in Sub-Saharan Africa. The Cockcoft-Gault, MDRD and
CKD-EPI equations were not evaluated against gold
standard to assess their validity in estimating GFR in
this population. We did not have estimates of albu-
minuria which are required for clinical and aetiological
diagnosis of CKD in clinical settings. This additional
information is important particularly in the interpret-
ation of eGFR > 60 where inaccuracies of the eGFR
equations are greatest. The nature of this study is cross-
sectional with high female to male participation, the latter
being a common trend in South African population
studies. Our study also has major strengths including
the provision of a complete picture of the CKD preva-
lence in a South African community setting with a high
prevalence of obesity, diabetes and hypertension. The
importance of assessing the GFR prediction equations
in specific ethnic population groups before they can be
recommended for use in each country has been highlighted.
Our study provides evidence against uncritical recom-
mendation of GFR estimators in this population, as this
may result in misclassification of individuals risk status
and inappropriate health actions.tors in diagnosing CKD stage 3–5 (kappa statistic and
Women Total
.13-0.40) 0.60 (0.52-0.68) 0.51 (0.44-0.58)
.44-0.70) 0.52 (0.45-0.58) 0.53 (0.47-0.59)
.20-0.47) 0.66 (0.58-0.74) 0.57 (0.49-0.64)
.52-0.76) 0.65 (0.59-0.72) 0.65 (0.59-0.71)
.30-0.60) 0.41 (0.34-0.47) 0.42 (0.36-0.48)
.71-0.97) 0.92 (0.87-0.96) 0.91 (0.86-0.95)
.34-0.70) 0.57 (0.49-0.65) 0.57 (0.50-0.64)
.35-0.64) 0.38 (0.32-0.45) 0.41 (0.34-0.47
.74-0.93) 0.78 (0.72-0.82) 0.79 (0.74-0.83)
.43-0.73) 0.54 (0.46-0.61) 0.55 (0.48-0.62)
BP, 4-v-MDRD, four variable Modification of Diet in Renal Disease.
Table 3 Determinants of CKD stage 3–5 (age, sex and cohort adjusted analyses)
Variables MDRD MDRD corrected CKD-EPI CKD-EPI corrected CG
Age (/year) 1.10 (1.08-1.11) 1.11 (1.09-1.13) 1.13 (1.11-1.15) 1.14 (1.11-1.17) 1.18 (1.15-1.21)
Female gender 3.08 (2.07-4.69) 2.42 (1.34-4.63) 2.56 (1.63-4.10) 2.09 (1.15-3.98) 0.74 (0.47-1.63)
Cohort 0.24 (0.15-0.39) 0.44 (0.19-0.91) 0.34 (0.19-0.58) 0.28 (0.09-0.66) 0.35 (0.18-0.64)
Current smoking 0.99 (0.71-1.39) 0.67 (0.37-1.17) 0.84 (0.55-1.26) 0.55 (0.38-1.02) 1.72 (1.09-2.77)
BMI (/kg/m2) 1.01 (0.99-1.03) 1.01 (0.98-1.05) 1.01 (0.98-1.04) 1.00 (0.96-1.04) 0.82 (0.79-0.86)
WC (/cm) 1.00 (0.99-1.01) 1.01 (1.00-1.03) 1.00 (0.99-1.02) 1.01 (0.99-1.02) 0.93 (0.91-0.94)
Hip circumference (/cm) 1.00 (0.99-1.02) 1.00 (0.99-1.02) 1.00 (0.99-1.02) 1.00 (0.98-1.02) 0.91 (0.89-0.93)
WHR (/unit) 0.66 (0.09-4.68) 14.63 (0.89-152) 1.01 (0.10-9.85) 9.86 (0.40-176) 0.03 (0.002-0.44)
SBP (/mm Hg) 1.00 (0.99-1.01) 0.99 (0.98-1.01) 1.00 (0.99-1.01) 0.99 (0.98-1.00) 0.99 (0.98-1.00)
DBP (/mm Hg) 1.00 (0.99-1.02) 1.00 (0.98-1.02) 1.00 (0.99-1.02) 1.00 (0.98-1.01) 0.98 (0.96-1.00)
Known hypertension 1.96 (1.35-2.90) 2.54 (1.35-5.16) 1.98 (1.27-3.18) 2.55 (1.31-5.31) 1.34 (0.82-2.23)
FBG (/mmol/L) 0.98 (0.93-1.03) 1.06 (0.99-1.13) 1.00 (0.94-1.06) 1.05 (0.97-1.13) 0.97 (0.90-1.04)
PostBG (/mmol/L) 0.97 (0.92-1.02) 0.96 (0.88-1.03) 0.96 (0.90-1.01) 0.95 (0.87-1.03) 0.93 (0.87-1.00)
HbA1c (/%) 0.95 (0.84-1.06) 1.16 (1.00-1.32) 1.00 (0.88-1.13) 1.15 (0.98-1.33) 1.00 (0.86-1.15)
TC (/mmol/L) 1.10 (0.96-1.26) 1.04 (0.85-1.27) 1.19 (1.02-1.39) 0.96 (0.78-1.18) 0.96 (0.80-1.15)
TG (/mmol/L) 1.13 (0.96-1.33) 1.37 (1.07-1.70) 1.23 (1.01-1.48) 1.37 (1.04-1.75) 0.97 (0.74-1.25)
HDL-C (/mmol/L) 0.88 (0.55-1.39) 0.44 (0.20-0.92) 0.95 (0.55-1.61) 0.54 (0.24-1.16) 2.12 (1.19-3.74)
LDL-C (/mmol/L) 1.09 (0.94-1.27) 1.02 (0.81-1.28) 1.17 (0.98-1.39) 0.92 (0.72-1.16) 0.88 (0.72-1.07)
Serum cotinine 0.95 (0.86-1.05) 0.93 (0.79-1.08) 0.95 (0.85-1.07) 0.90 (0.76-1.07) 1.22 (1.07-1.39)
GGT (/unit) 1.09 (0.86-1.38) 1.17 (0.79-1.72) 1.03 (0.76-1.38) 1.20 (0.78-1.83) 1.25 (0.88-1.76)
Any diabetes 1.17 (0.83-1.63) 1.55 (0.96-2.46) 1.16 (0.79-1.69) 1.55 (0.94-2.55) 1.12 (0.73-1.71)
Abbreviations: BMI, body mass index; CG, Cockcroft-Gault; CKD-EPI, Chronic Kidney Disease Collaboration Epidemiology; DBP, diastolic blood pressure; FBG,
fasting blood glucose; GGT, gamma glutamyltransferase; HbA1c, glycosylated haemoglobin A1c; HDL-C, high density lipoprotein-cholesterol; LDL-C, low density
lipoprotein-cholesterol; 4-v-MDRD, four variable Modification of Diet in Renal Disease; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WHR,
waist-to-hip ratio.
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The findings of the present study have significant clinical
and public health implications. We studied a community
with a high burden of obesity, hypertension and diabetes
that may also be at increased risk of CKD. It is highly
likely that some of the participants identified to be at
risk or have CKD in the present study were not aware of
their status as this was a community-based research
project. Such individuals should be monitored to delay
or prevent the progression of the diseases. The South
African Renal Society CKD guidelines recommends theTable 4 Multivariable adjusted odd ratios (and 95% confiden
Variables MDRD MDRD corrected
Age (/year) 1.09 (1.08-1.11) 1.11 (1.09-1.14)
Female gender 2.88 (1.92-4.38) 2.15 (1.18-4.14)
Cohort 0.27 (0.16-0.44) 0.50 (0.21-1.04)
Known hypertension 1.96 (1.35-2.90) 2.42 (1.28-4.94)
Triglycerides (/mmol/L) NS 1.33 (1.04-1.67)
Body mass index (/kg/m2) NS NS
Total cholesterol (/mmol/L) NS NS
CKD-EPI, Chronic Kidney Disease Collaboration Epidemiology; 4-v-MDRD, four variab
For CKD-EPI, TC was only significant when triglycerides (NS) was removed from the
cholesterol was not significant. For Cockroft-Gault: Hip was significant when replaci
was significant only in the presence of body mass index in the model.use of Cockcroft-Gault or MDRD equations, however,
our study demonstrated a poor agreement between the
two equations in the Mixed Ancestry population groups.
Other African studies have suggested omission of the
ethnicity correction factor from either the MDRD or
CKD-EPI equation. Our study found a high positive cor-
relation and good agreement when the ethnicity factor
was included. The findings of the present study suggest
that the Cockcoft-Gault equation be replaced by the
CKD-EPI equation upon validation against measured
GFR to prevent overestimation of CKD, particularly in ace intervals) for the determinants of CKD stage 3-5
CKD-EPI CKD-EPI corrected Cockroft-Gault
1.14 (1.11-1.15) 1.14 (1.11-1.17) 1.21 (1.18-1.25)
2.15 (1.36-3.47) 1.97 (1.07-3.83) 1.43 (0.84-2.45)
0.39 (0.22-0.68) 0.31 (0.10-0.73) 0.30 (0.14-0.60)
1.97 (1.25-3.15) 2.34 (1.20-4.93) 2.76 (1.56-5.00)
NS 1.33 (1.00-1.71) NS
NS NS 0.81 (0.77-0.85)
1.19 (1.02-1.39) NS NS
le Modification of Diet in Renal Disease.
model, however triglycerides in the presence of other covariates except total
ng waist circumference in the models, not in its presence. And hypertension
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http://www.biomedcentral.com/1471-2369/14/75country with limited health care resources. Identifica-
tion of an eGFR equation that can be used in primary or
secondary healthcare institution may lead to the intro-
duction of automated eGFR reporting, and better man-
agement of the disease. Studies in the United Kingdom
and Australia have shown that automated reporting of
eGFR with serum creatinine increased primary care pro-
vider awareness of CKD [39,40], and in other countries
nephrology visits [41].
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